Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNK009
- Development stage
- Preclinical
- Lead developer
- Lynk Pharmaceuticals
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
LNK009 is an oral, preclinical-stage proteolysis-targeting chimera (PROTAC) designed to selectively degrade signal transducer and activator of transcription 6 (STAT6). Developed by Lynk Pharmaceuticals using its proprietary IsoNova protein degradation platform, LNK009 is being investigated for the treatment of autoimmune and inflammatory diseases, including asthma, atopic dermatitis, inflammatory bowel disease (IBD), and psoriasis. By targeting STAT6 for degradation, LNK009 aims to inhibit the IL-4/IL-13 signaling pathway, which plays a key role in type 2 helper T cell (Th2)-mediated allergic inflammation.
02
Targets
STAT6 (Signal Transducer and Activator of Transcription 6)
Beyond the preview
Go deeper on LNK009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNK009.